deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 38-arm NCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Molecular Analysis for Therapy Choice (MATCH)

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Lymphoma Advanced Malignant Solid Neoplasm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Exocrine Pancreas Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Hematopoietic and Lymphoid Cell Neoplasm Kidney Carcinoma Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Corpus Neoplasm Malignant Uterine Neoplasm Melanoma Multiple Myeloma Ovarian Carcinoma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Malignant Uterine Corpus Neoplasm Recurrent Melanoma Recurrent Multiple Myeloma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Multiple Myeloma Skin Carcinoma Thyroid Gland Carcinoma
Interventions Adavosertib Afatinib Afatinib Dimaleate Binimetinib Biopsy Procedure Biospecimen Collection Capivasertib Computed Tomography Copanlisib Copanlisib Hydrochloride Crizotinib Cytology Specimen Collection Procedure Dabrafenib Dabrafenib Mesylate Dasatinib Defactinib Defactinib Hydrochloride Echocardiography Test Erdafitinib Fexagratinib Ipatasertib Laboratory Biomarker Analysis Larotrectinib Larotrectinib Sulfate Magnetic Resonance Imaging Multigated Acquisition Scan Nivolumab Osimertinib PI3K-beta Inhibitor GSK2636771 Palbociclib Pertuzumab Radiologic Examination Radionuclide Imaging Relatlimab Sapanisertib Sunitinib Malate Taselisib Trametinib Trastuzumab Trastuzumab Emtansine Ulixertinib Vismodegib
Updated 108 times since 2017 Last updated: Mar 12, 2026 Started: Aug 17, 2015 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02465060, this PHASE2 trial focuses on Advanced Lymphoma and Advanced Malignant Solid Neoplasm and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 108 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma. II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms. IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens. OUTLINE: STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes. STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 38 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section) STEPS 2, 4, 6...

PRIMARY OBJECTIVE:

I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE:

STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes.

STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 38 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section)

STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.

STEP 8 (Optional Research): Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes.

Additionally, patients may undergo a computed tomography (CT) scan, magnetic resonance imaging, and/or radionuclide imaging throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot~Feb 2026 – present · 2 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 33 days · monthly snapshot~Mar 2026 – present · 33 days · monthly snapshot

Change History

108 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

▶ Show 103 earlier versions

  1. Dec 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  7. May 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  8. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  9. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  12. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  13. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  14. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  15. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  16. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  17. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  18. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  19. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  20. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  21. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  22. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  23. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  24. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  25. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  26. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  27. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  28. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  29. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  30. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  31. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  32. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  33. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  34. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  35. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  36. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  37. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  38. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  39. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  40. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  41. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  42. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  43. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  44. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  45. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  46. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  47. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  48. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  49. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  50. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  51. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  52. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  53. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  54. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  55. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  56. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  57. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  58. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  59. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  60. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  61. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  62. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  63. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  64. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  65. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  66. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  67. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  68. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  69. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  70. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  71. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  72. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  73. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  74. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  75. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  76. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  77. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  78. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  79. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  80. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

  81. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  82. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  83. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  84. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  85. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  86. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  87. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  88. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  89. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  90. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  91. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  92. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  93. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  94. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  95. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  96. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  97. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  98. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  99. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  100. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  101. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  102. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  103. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abington, United States , Adrian, United States , Aitkin, United States , Albuquerque, United States , Allentown, United States , Alliance, United States , Alton, United States , Altoona, United States , American Fork, United States and 780 more locations